中东和非洲人类疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型（颗粒佐剂、乳液佐剂、组合佐剂及其他）、应用（流感、肝炎、人乳头瘤病毒 (HPV) 及其他）和最终用户（制药和生物技术公司、CMO 和 CRO 及其他）
慢性病患病率上升促进中东和非洲人类疫苗佐剂市场
慢性病患病率上升推动了对疫苗佐剂的需求。疫苗中添加佐剂以增强功效和人体的免疫反应。它们通过刺激更强烈和更持久的免疫反应来帮助提高疫苗的有效性。随着对预防和管理慢性病的疫苗的需求不断增长，对佐剂的需求也在增加。心血管疾病、癌症、糖尿病和呼吸系统疾病等慢性病在全球范围内呈上升趋势。根据世界卫生组织的数据，非传染性疾病相关死亡人数最多的是心血管疾病，每年造成 1700 万人死亡，其次是癌症、慢性呼吸道疾病和糖尿病（包括与肾脏相关的死亡）。此外，根据世界心脏联盟的数据，高胆固醇每年导致 440 万人死亡，而 24% 的心血管相关死亡可归因于高低密度脂蛋白 (LDL) 胆固醇。因此，慢性病负担的增加导致对可以预防或控制这些疾病的疫苗的需求不断增长。肝炎的患病率也在增加。肝炎疫苗中的佐剂旨在引发强大而持久的免疫力，特别是对标准疫苗制剂反应不佳的人群，例如患有潜在疾病或与年龄相关的免疫衰老的人群。根据世界卫生组织的数据，全世界有超过 3.5 亿人患有乙型或丙型肝炎。在所有类型的肝炎中，有几种可以通过接种疫苗预防。根据世界卫生组织的一项研究，到 2030 年，中低收入国家估计有 450 万人通过接种疫苗可以避免因肝炎而过早死亡。因此，慢性病的日益流行推动了中东和非洲人用疫苗佐剂市场的增长。
中东和非洲人用疫苗佐剂市场概览
沙特阿拉伯计划将 40% 的制药行业本地化，并减少对进口的依赖，作为其国家转型计划的一部分。在沙特阿拉伯，经济和社会变化导致久坐生活方式的转变，从而导致肥胖症患病率不断上升，代谢综合征预计也会上升。此外，患者缺乏疾病意识和对疾病传播的了解，这也增加了该国传染病的流行率。例如，根据 2023 年在 PubMed 上发表的一项研究“沙特阿拉伯和阿联酋的乙肝病毒感染：公共卫生挑战及其补救措施”，沙特阿拉伯即使在实施大规模疫苗接种计划后，在乙肝病毒治疗和管理方面仍面临严峻挑战。同样，根据 ICO/IARC 信息中心 2023 年关于 HPV 和癌症的报告，沙特阿拉伯有 1070 万 15 岁及以上的女性面临患 HPV 相关宫颈癌的风险。因此，阿联酋传染病的日益流行刺激了对人类疫苗佐剂的需求。近年来，沙特阿拉伯王国在医疗保健和制药领域投入了大量资金，旨在提高国内生产、研发能力。这一战略重点为潜在增长奠定了基础，影响了中东和非洲的人类疫苗佐剂市场。在沙特阿拉伯，法赫德国王医疗城、费萨尔国王专科医院及研究中心和卫生部等机构积极参与推动医疗保健研究，包括与疫苗和佐剂相关的研究。对研究设施和医疗基础设施的此类投资表明了它们致力于为全球疫苗领域做出贡献。预计它还将为佐剂研究和开发进步铺平道路。
中东和非洲人用疫苗佐剂市场收入及预测至 2030 年（百万美元）
中东和非洲人用疫苗佐剂市场细分
中东和非洲人用疫苗佐剂市场分为类型、应用、最终用户和国家。
根据类型，中东和非洲人用疫苗佐剂市场分为颗粒佐剂、乳剂佐剂、组合佐剂和其他。颗粒佐剂部分在 2022 年占据了最大的市场份额。
就应用而言，中东和非洲人用疫苗佐剂市场分为流感、肝炎、人乳头瘤病毒 (HPV) 等。流感部分在 2022 年占据了最大的市场份额。
按最终用户划分，中东和非洲人用疫苗佐剂市场细分为制药和生物技术公司、CMO 和 CRO 等。制药和生物技术公司部分在 2022 年占据了最大的市场份额。
按国家/地区划分，中东和非洲人用疫苗佐剂市场细分为沙特阿拉伯、南非、阿联酋和中东及非洲其他地区。 2022 年，沙特阿拉伯占据了中东和非洲人类疫苗佐剂市场的主导份额。
诺华股份公司 (Novartis AG)、CSL 有限公司、Seppic SA、Croda International Plc、Novavax Inc 和 Phibro Animal Health Corp 是中东和非洲人类疫苗佐剂市场的一些领先公司。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Human Vaccine Adjuvants Market - Key Market Dynamics
4.1 Middle East & Africa Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:
5. Human Vaccine Adjuvants Market - Middle East & Africa Market Analysis
5.1 Middle East & Africa Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Middle East & Africa Human Vaccine Adjuvants Market Forecast Analysis
6. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by Type
6.1 Particulate Adjuvant
6.1.1 Overview
6.1.2 Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
6.2.1 Overview
6.2.2 Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
6.3.1 Overview
6.3.2 Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
6.4.1 Overview
6.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by Application
7.1 Influenza
7.1.1 Overview
7.1.2 Influenza: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
7.2.1 Overview
7.2.2 Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
7.3.1 Overview
7.3.2 Human Papilloma Virus (HPV): Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Human Vaccine Adjuvants Market Analysis - by End User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
8.2.1 Overview
8.2.2 CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Human Vaccine Adjuvants Market - Country Analysis
9.1 Middle East & Africa
9.1.1 Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
9.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.1.2 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.1.3 Saudi Arabia Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.2 South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 South Africa Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.2.2 South Africa Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.2.3 South Africa Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.3 United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.3.2 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.3.3 United Arab Emirates Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.4 Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.4.2 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.4.3 Rest of Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User
10. Industry Landscape
10.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 CSL Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Seppic SA
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Croda International Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Novavax Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Phibro Animal Health Corp
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
List of Tables
Table 1. Middle East & Africa Human Vaccine Adjuvants Market Segmentation
Table 2. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 19. Glossary of Terms, Human Vaccine Adjuvants Market
List of Figures
Figure 1. Middle East & Africa Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Middle East & Africa Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Middle East & Africa Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Middle East & Africa Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. Saudi Arabia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. South Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. United Arab Emirates Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Rest of Middle East & Africa Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
1. Novartis AG
2. CSL Ltd
3. Seppic SA
4. Croda International Plc
5. Novavax Inc
6. Phibro Animal Health Corp
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa human vaccine adjuvants market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa human vaccine adjuvants market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.